Summary
The Trump administration announced that an old drug called leucovorin would be repurposed to treat autism, despite limited supporting evidence and lack of extensive research. Experts and autism groups expressed concern over the decision, stating that the drug's effectiveness for autism symptoms is not well supported by studies.
Key Facts
- Leucovorin is a derivative of vitamin B.
- The Trump administration promoted leucovorin as a treatment for autism without extensive studies.
- Experts, including Dr. Richard Frye, were surprised by the quick approval of the drug.
- Autism researchers and groups distanced themselves from the leucovorin decision.
- Some researchers note that autism is mainly influenced by genetics.
- Leucovorin may be promising for specific cases with a folate deficiency, but requires more study.
- Current recommendations suggest the drug should only be used in controlled clinical trials.
- The connection between folate levels and autism is uncertain, as shown by past research.
